Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05325346 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
A Phase 1 study of Heparin-induced Thrombocytopenia, sponsored by Veralox Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05325346: Completed Phase 1 study of Heparin-induced Thrombocytopenia, sponsored by Veralox Therapeutics.
NCT05325346 is a Phase 1 study of Heparin-induced Thrombocytopenia that has completed, run by Veralox Therapeutics. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05325346, a Phase 1 study of Heparin-induced Thrombocytopenia, has completed, sponsored by Veralox Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is designed to characterize the safety and tolerability of VLX-1005 and argatroban administered intravenously, either alone or in combination; and the pharmacokinetics and pharmacodynamics and potential interaction of both agents in a population of healthy subjects.
Primary Outcome
Measure the effects of argatroban on the maximum plasma concentration (Cmax) of VLX-1005
Conditions Studied
Interventions
- DRUG VLX-1005
- DRUG Argatroban
Study Locations (1)
Nebraska
- Celerion, Inc. - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2022-04-14 |
| Phase | Phase 1 |
What the finished NCT05325346 record still lists
NCT05325346 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Heparin-induced Thrombocytopenia appearing as the primary indexed condition, and to 2 interventions - of which VLX-1005 is the first listed.
NCT05325346 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT05325346 about?
NCT05325346 is a clinical study titled "A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects". The study is designed to characterize the safety and tolerability of VLX-1005 and argatroban administered intravenously, either alone or in combination; and the pharmacokinetics and pharmacodynamics and potential interaction of both agents in a population of healthy subjects.
What is the current status of trial NCT05325346?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2022-03-07. Estimated completion is 2022-04-14.
What conditions does trial NCT05325346 study?
This clinical trial studies the following conditions: Heparin-induced Thrombocytopenia.
What interventions are being tested in trial NCT05325346?
The interventions under investigation include: VLX-1005 (DRUG), Argatroban (DRUG).
Who is sponsoring clinical trial NCT05325346?
This trial is sponsored by Veralox Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05325346 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heparin-induced Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05325346's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI